Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R
Evidence suggests that combining GLP-1 receptor agonists with lifestyle interventions can lead to more pronounced weight loss and improvements in cardiometabolic biomarkers, emphasizing a synergistic effect
Tracking SHBG is useful because changes alter free hormone availability
The FDA has approved it, and its available as an oral medication
Alcohol considerations Alcohol interacts with semaglutide in ways that affect both efficacy and side effects
However, it matters legally because: Different labels have different warnings Off-label use (using Ozempic for weight loss) creates specific legal issues Your doctors prescription details affect your case 3